hematology education - European Hematology Association

More documents

Recommendations

Info

hematology education the education program for the annual congress of the European Hematology Association EHA Executive Board W Fibbe, President, The Netherlands R Foà, President Elect, Italy E Hellström-Lindberg, Past President, Sweden H Döhner, Treasurer, Germany I Roberts, Secretary, United Kingdom EHA Councilors E Berntorp, Sweden C Camaschella, Italy C Chomienne, France U Jäger, Austria C Lacombe, France J Sierra, Spain R Skoda, Switzerland I Touw, The Netherlands EHA Local Organizing Committee 14 th Congress R Hehlmann, Congress President, Germany B Dörken, Germany D Niederwieser, Germany E Thiel, Germany EHA Scientific Program Committee 14 th Congress R Skoda, Chair, Switzerland H Büller, The Netherlands C Chomienne, France J Cools, Belgium F Lo Coco, Italy C Niemeyer, Germany I Peake, United Kingdom G Salles, France M Theobald, The Netherlands S Thein, United Kingdom EHA Scientific Program Committee Advisory Board 14 th Congress N Avent, United Kingdom M Baccarani, Italy C Beaumont, France E Berntorp, Sweden J Cornelissen, The Netherlands C Craddock, United Kingdom N Cross, United Kingdom T Enver, United Kingdom C Gachet, France G Gaidano, Italy P Ghia, Italy W Hofmann, Germany B Huntly, United Kingdom J Ingerslev, Denmark S Izraeli, Israel B Lämmle, Switzerland L Malcovati, Italy M Manz, Switzerland R Pieters, The Netherlands M Piris, Spain J San Miguel, Spain B Schlegelberger, Germany R Schlenk, Germany M Trneny, Czech Republic A Urbano Ispizua, Spain A Waage, Norway EHA Education Committee A Green, Chair, United Kingdom M Arat, Turkey E Berntorp, Sweden C Chomienne, France C Craddock, United Kingdom W Fibbe, The Netherlands E Hellström-Lindberg, Sweden D Jasmin, France F Lo Coco, Italy H Servé, Germany EHA Press Committee 2009 A Hagenbeek, Chair, The Netherlands W Fibbe, The Netherlands R Hehlmann, Germany I Roberts, United Kingdom R Skoda, Switzerland EHA Publication Committee W Fibbe, Chair, The Netherlands M Cazzola, Italy R Foà, Italy C Lacombe, France S McCann, Ireland European Hematology Association E-mail: info@ehaweb.org, Website: www.ehaweb.org
Education Book Reviewers We would like to thank the reviewers of the manuscripts for the Education Book. M André, Belgium N Avent, United Kingdom M Baccarani, Italy E Berntorp, Sweden A Biondi, Italy M Björkholm, Sweden F Caligaris-Cappio, Italy A Cohen, United Kingdom J Cools, Belgium J Cornelissen, The Netherlands C Craddock, United Kingdom H Einsele, Germany T Enver, United Kingdom W Fibbe, The Netherlands G Gaidano, Italy A Gratwohl, Switzerland A Green, United Kingdom E Hellström-Lindberg, Sweden W Hofmann, Germany S Izraeli, Israel M Laffan, United Kingdom T Lamy, France B Lämmle, Switzerland F Lo Coco, Italy H Pahl, Germany R Pieters, The Netherlands M Piris, Spain P Rousselot, France G Salles, France J San Miguel, Spain R Schlenk, Germany I Roberts, United Kingdom S Thein, United Kingdom M Theobald, The Netherlands
Page 1 and 2: hematology education the education
Page 3: Copyright Information ©2009 by Eur
Page 7 and 8: Acute lymphoblastic leukemia 1-7 Ge
Page 9 and 10: C.G. Mullighan Department of Pathol
Page 11 and 12: is required for normal B-lymphoid c
Page 13 and 14: Given the tremendous insights gaine
Page 15 and 16: 78. Mullighan CG, Radtke I, Zhang J
Page 17 and 18: gene expression via chromatin modif
Page 19 and 20: This has prompted the hypothesis th
Page 21 and 22: S. Izraeli Sheba Medical Center and
Page 23 and 24: e the presence of lineage specific
Page 25 and 26: E. Gudgin B. Huntly Department of H
Page 27 and 28: Figure 2. A proposed roadmap for LS
Page 29 and 30: differentiation previously alluded
Page 31 and 32: Nat Rev Cancer 2004;4:394-400. 64.
Page 33 and 34: esent reliable and robust markers f
Page 35 and 36: with NPM1 mutations. 26 Recently, s
Page 37 and 38: 199;82:3556-9. 60. Diverio D, Rossi
Page 39 and 40: such as lenalidomide are being inve
Page 41 and 42: possible favourable impact from hig
Page 43 and 44: leukemia: final results of AML-13,
Page 45 and 46: leukemia and myelodysplastic syndro
Page 47 and 48: suggests a role for macrophages in
Page 49 and 50: studies in the future will undoubte
Page 51 and 52: 56. Mannucci PM. How I treat patien
Page 53 and 54: score may become part of an initial
Page 55 and 56:
vide type 2A, 4 and correlates to a
Page 57 and 58:
eply to a rebuttal. J Thromb Haemos
Page 59 and 60:
leeding or surgery. For this infusi
Page 61 and 62:
or invasive procedures. 16 Two retr
Page 63 and 64:
U. Klein Institute for Cancer Genet
Page 65 and 66:
known to be activated as a result o
Page 67 and 68:
ulation either into a GC-response w
Page 69 and 70:
R. Rosenquist Department of Genetic
Page 71 and 72:
that expression of CD38 correlated
Page 73 and 74:
arrays was also predictive of poor
Page 75 and 76:
901. 41. Kröber A, Bloehdorn J, Ha
Page 77 and 78:
are inferior to those with mutated
Page 79 and 80:
23: 2971-9. 8. Tam CS, O’Brien S,
Page 81 and 82:
originates in a hematopoietic stem
Page 83 and 84:
Some evidence for this comes from s
Page 85 and 86:
chronic myelogenous leukemia patien
Page 87 and 88:
ple, substitutions at M244, L248, F
Page 89 and 90:
ABL T315I mutation have been report
Page 91 and 92:
H. Kantarjian J. Cortes Department
Page 93 and 94:
Table 3. Characteristics of second
Page 95 and 96:
nilotinib, where colony growth with
Page 97 and 98:
F. Efficace 1 M.A. Sprangers 2 1 He
Page 99 and 100:
patients with CLL showing better re
Page 101 and 102:
Table 2. Minimum standard criteria
Page 103 and 104:
40. Fayers P, Hays R. Assessing Qua
Page 105 and 106:
Table 1. Definitions. Term Definiti
Page 107 and 108:
lation groups. The role of a predic
Page 109 and 110:
E. Estey Fred Hutchinson Cancer Res
Page 111 and 112:
informative the prior, the more dat
Page 113 and 114:
powered phase 3 trials.” Examinat
Page 115 and 116:
50% of DLBCL targeting various prot
Page 117 and 118:
the class III, and the breakpoints
Page 119 and 120:
with poor outcome in sporadic Burki
Page 121 and 122:
tory DLBCL. 23 Twelve of fifty-five
Page 123 and 124:
Figure 3. B-cell-receptor signaling
Page 125 and 126:
Cattoretti G et al. NF{kappa}B acti
Page 127 and 128:
increasing toxicity. 4 Thus, combin
Page 129 and 130:
vage therapies with minimal toxicit
Page 131 and 132:
E. Dzierzak Erasmus Medical Center,
Page 133 and 134:
associated stem cells contributes t
Page 135 and 136:
et al. Comparative study of stromal
Page 137 and 138:
their biologic property to eliminat
Page 139 and 140:
HSC to mature cells, and a reduced
Page 141 and 142:
K. Lapid T. Lapidot Department of I
Page 143 and 144:
HSPCs from the BM reservoir in resp
Page 145 and 146:
mented (reviewed in 90). The BM is
Page 147 and 148:
57. Kollet O, Dar A, Shivtiel S, Ka
Page 149 and 150:
somatic hypermutation targets vario
Page 151 and 152:
19. Mauz-Korholz C, Gorde-Grosjean
Page 153 and 154:
2.In advanced-stages, could an aggr
Page 155 and 156:
Table 1. Prognostic meaning of FDG-
Page 157 and 158:
patients with advanced Hodgkin Lymp
Page 159 and 160:
D.A. Eichenauer A. Engert First Dep
Page 161 and 162:
arms had initially achieved CR). FF
Page 163 and 164:
G. Morgan K. Boyd Brookes Lawley Bu
Page 165 and 166:
Classification of myeloma Progress
Page 167 and 168:
translocations (t(4;14), t(14;16),
Page 169 and 170:
N.C. Munshi Boston VA Healthcare Sy
Page 171 and 172:
approved for the treatment of MM, a
Page 173 and 174:
Tai YT et al. p38MAPK inhibition en
Page 175 and 176:
Table 1. Post-induction and postran
Page 177 and 178:
Table 4. Randomized trials on treat
Page 179 and 180:
patients with multiple myeloma. Hae
Page 181 and 182:
improvement when treated with these
Page 183 and 184:
some and protein synthesis were dif
Page 185 and 186:
S.D. Nimer Division of Hematologic
Page 187 and 188:
trols the movement of cells from G2
Page 189 and 190:
M. Cazzola L. Malcovati Department
Page 191 and 192:
vivals and probabilities of leukemi
Page 193 and 194:
Table 5. WPSS risk-adapted treatmen
Page 195 and 196:
erythroid dysplasia in patients wit
Page 197 and 198:
myeloid malignancies were detected,
Page 199 and 200:
nani A, et al. Cytogenetic studies
Page 201 and 202:
anemia and prior history of PV have
Page 203 and 204:
improvement in the degree of anemia
Page 205 and 206:
Table 2. Proposed approach to treat
Page 207 and 208:
Blood 2002;99:2255-8. 62. Hessling
Page 209 and 210:
Table 1. Published trials of interf
Page 211 and 212:
een published, as shown in Tables 1
Page 213 and 214:
The current development of JAK2 inh
Page 215 and 216:
78. Gilbert HS. Long term treatment
Page 217 and 218:
genetic abnormality in childhood MD
Page 219 and 220:
Primary myelodysplastic syndrome wi
Page 221 and 222:
ical care and elucidating the patho
Page 223 and 224:
Current controversies in the treatm
Page 225 and 226:
elapses in the donor group, but thi
Page 227 and 228:
study. Despite such an internationa
Page 229 and 230:
M.L. Randi M.C. Putti 1 Dept of Med
Page 231 and 232:
nosis in agreement with Passamonti
Page 233 and 234:
References 1. Adamson JW, Fialkow P
Page 235 and 236:
N. Mohandas New York Blood Center,
Page 237 and 238:
Table 1. Gene mutation in inherited
Page 239 and 240:
normal surface area. The inheritanc
Page 241 and 242:
M.H. Steinberg Department of Medici
Page 243 and 244:
Priapism Priapism occurs in about 4
Page 245 and 246:
16. Hoppe C, Klitz W, Noble J, Vigi
Page 247 and 248:
Table 1. Causes of an absolute eryt
Page 249 and 250:
een suggested. 24 In the congenital
Page 251 and 252:
ine with relatively high doses of b
Page 253 and 254:
immune recovery) 58 and disease rel
Page 255 and 256:
References 1. Storb R. Allogeneic h
Page 257 and 258:
geneic hematopoietic cell transplan
Page 259 and 260:
isk and severity of acute and chron
Page 261 and 262:
are simply delayed. The persistence
Page 263 and 264:
Gualandi F, et al. Allogeneic bone
Page 265 and 266:
Figure 1. Outcome of HSCT by donor
Page 267 and 268:
RIC HSCT can be applied to patients
Page 269 and 270:
P.H. Reitsma Einthoven Laboratory f
Page 271 and 272:
seems to be associated with age-rel
Page 273 and 274:
ia due to a previously unrecognized
Page 275 and 276:
D-dimer test evaluations, and showe
Page 277 and 278:
This is also the case, even in esse
Page 279 and 280:
A. Kleinjan H.R. Büller Department
Page 281 and 282:
Figure 1. The new anticoagulants an
Page 283 and 284:
nant tissue factor pathway inhibito
Page 285 and 286:
gens. 13,14 A study by Noumsi and M
Page 287 and 288:
Table 1. Sickle cell hemolytic tran
Page 289 and 290:
Intern Med 1980;93:231-4. 57. Culli
Page 291 and 292:
may be extended to 7 days once ster
Page 293 and 294:
have a full medical assessment and
Page 295 and 296:
ethasone versus glycosylated G-CSF
Page 297 and 298:
Table 1. Transfusion guidelines for
Page 299 and 300:
Pretransfusion testing and product
Page 301 and 302:
lood components from blood-related
Page 303 and 304:
Precursor NK cell neoplasms NK cell
Page 305 and 306:
Table 2. Clinical and biological fe
Page 307 and 308:
ehavior between cytotoxic T and NK
Page 309 and 310:
a single institute survey in Taiwan
Page 311 and 312:
matosus, as well as in patients wit
Page 313 and 314:
Figure 3. PCR for the TCRβ and TCR
Page 315 and 316:
Wotherspoon A, et al. T-cell large
Page 317 and 318:
antibody to Annexin A1, a very spec
Page 319 and 320:
Table 2. Responses to rituximab in
Page 321 and 322:
monoclonal antibody, in the treatme
show all

hematology education - European Hematology Association

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?